Video Experimental Relacionado

Updated: Feb 19, 2026

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma

Published on: April 15, 2022

Estadificación genómica de consenso IMS-IMWG 2025 predice resultados con regímenes cuádruples basados en daratumumab

Kylee H Maclachlan¹, Carlyn Rose Tan², Tala Shekarkhand²

¹Memorial Sloan Kettering Cancer Center, New York, New York, United States.

|February 17, 2026

Resumen

La nueva estadificación genómica de consenso (CGS) para el mieloma múltiple recién diagnosticado (NDMM) de alto riesgo predice eficazmente la supervivencia libre de progresión, incluso con negatividad de la enfermedad residual mínima después del tratamiento.

Palabras clave:

mieloma múltiple estadificación genómica supervivencia libre de progresión enfermedad residual mínima daratumumab ensayos clínicos estratificación de riesgos

Más Videos Relacionados

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

Predictive Immune Modeling of Solid Tumors

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

Videos de Conceptos Relacionados

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...